|
|
|
|
|||||
|
|
|
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis
Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate in 1H26
Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis actively enrolling
Approximately $126.9 million cash, cash equivalents and restricted cash as of December 31, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA trial
FREDERICK, Md., March 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“we”, the “Company” or “Cartesian”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today reported financial results for the year ended December 31, 2025, and outlined recent business updates.
“Building on a productive year, we look forward to a potentially transformative 2026 as we advance Descartes-08 across several autoimmune indications,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. “Our top priority remains delivering on our Phase 3 AURORA trial in myasthenia gravis (MG), for which we are on track to enroll approximately 100 patients. This trial represents a crucial opportunity to demonstrate the potential of Descartes-08 to improve patient outcomes and redefine the standard-of-care for MG. Descartes-08’s ease of use, including, flexible, convenient outpatient administration with no preconditioning chemotherapy, combined with deep and durable responses observed through 12 months following a single course of treatment, and a favorable safety profile, underscore our belief that Descartes-08 holds significant promise to deliver meaningful benefit to patients.”
Dr. Brunn continued, “Beyond MG, we are working to activate sites for our Phase 2 TRITON trial of Descartes-08 in myositis, which we plan to initiate in the first half of 2026. In parallel, we are also excited to explore potentially enhanced cell therapy delivery options of existing product candidates and next generation agents in development through in-vivo platforms with multiple feasibility studies underway. With an upcoming year of focused clinical execution, we believe we are well-positioned to fill the significant unmet need that remains within the autoimmune treatment landscape.”
Pipeline Progress and Anticipated Milestones
Corporate Updates
Full Year 2025 Financial Results
About Descartes-08
Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous CAR-T product targeting BCMA in clinical development for generalized MG and myositis, specifically dermatomyositis and antisynthetase syndrome. In contrast to conventional DNA-based CAR T-cell therapies, Cartesian’s CAR-T administration is designed to not require preconditioning chemotherapy, can be administered in the outpatient setting, and does not carry the risk of genomic integration associated with cancerous transformation. Descartes-08 has been granted Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation by the U.S. Food and Drug Administration for the treatment of MG, and Rare Pediatric Disease Designation for the treatment of juvenile dermatomyositis.
About Cartesian Therapeutics
Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and in Phase 1/2 clinical development of juvenile dermatomyositis with plans to initiate a Phase 2 trial in myositis, specifically dermatomyositis and antisynthetase syndrome in the first half of 2026. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.
Forward-Looking Statements
Any statements in this press release about the future expectations, plans and prospects of the Company, including without limitation, statements regarding the Company’s expected cash resources and cash runway, the ability of the Company’s product candidates to be administered in an outpatient setting or without the need for preconditioning lymphodepleting chemotherapy, the potential of Descartes-08, or any of the Company’s other product candidates to treat MG, juvenile MG, myositis, JDM, or any other disease, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, including the ongoing Phase 3 AURORA trial of Descartes-08 in MG, the planned Phase 2 TRITON trial of Descartes-08 in myositis, and the planned Phase 2 pediatric HELIOS trial of Descartes-08 in autoimmune diseases, including JDM, the anticipated timing or the outcome of the FDA’s review of the Company’s regulatory filings, including the number of trials that may be necessary in order to obtain marketing approval, the potential for in-vivo delivery of the Company’s product candidates, the Company’s ability to conduct its clinical trials and preclinical studies, the timing or making of any regulatory filings, the anticipated timing or outcome of selection of developmental product candidates, the ability of the Company to enter into and maintain potential collaborations or partnerships, the novelty of treatment paradigms that the Company is able to develop, the potential of any therapies developed by the Company to fulfill unmet medical needs, and enrollment in the Company’s clinical trials and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial and whether results of early clinical trials will be indicative of the results of later clinical trials, the ability to predict results of studies performed on human beings based on results of studies performed on non-human subjects, the unproven approach of the Company’s technology, potential delays in enrollment of patients, undesirable side effects of the Company’s product candidates, political uncertainty, the Company’s reliance on third parties to conduct its clinical trials, the Company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company’s recurring losses from operations and negative cash flows, substantial fluctuation in the price of the Company’s common stock, risks related to geopolitical conflicts, pandemics, and macroeconomic impacts, and other important factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward-looking statements included in this press release, except as required by law.
| Cartesian Therapeutics, Inc. and Subsidiaries Consolidated Balance Sheets (Amounts in thousands, except share data and par value) | ||||||||
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 125,139 | $ | 212,610 | ||||
| Accounts receivable | 1,115 | 872 | ||||||
| Prepaid expenses and other current assets | 3,022 | 3,144 | ||||||
| Total current assets | 129,276 | 216,626 | ||||||
| Property and equipment, net | 12,185 | 9,912 | ||||||
| Right-of-use assets, net | 5,601 | 5,535 | ||||||
| In-process research and development assets | 93,900 | 150,600 | ||||||
| Goodwill | 48,163 | 48,163 | ||||||
| Long-term restricted cash | 1,735 | 1,669 | ||||||
| Investment | — | 2,000 | ||||||
| Long-term prepaid expenses and other assets | 5,551 | 518 | ||||||
| Total assets | $ | 296,411 | $ | 435,023 | ||||
| Liabilities and stockholders’ deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,288 | $ | 288 | ||||
| Accrued expenses and other current liabilities | 9,498 | 12,076 | ||||||
| Lease liabilities | 4,151 | 2,851 | ||||||
| Contingent value right liability | — | 7,761 | ||||||
| Total current liabilities | 14,937 | 22,976 | ||||||
| Lease liabilities, net of current portion | 8,525 | 11,133 | ||||||
| Warrant liability | 141 | 3,836 | ||||||
| Contingent value right liability, net of current portion | 392,100 | 387,739 | ||||||
| Deferred tax liabilities, net | 6,948 | 16,141 | ||||||
| Total liabilities | 422,651 | 441,825 | ||||||
| Stockholders’ deficit: | ||||||||
| Series A Preferred Stock, $0.0001 par value; 134,904.563 shares authorized as of December 31, 2025 and 2024; 120,790.402 shares issued and outstanding as of December 31, 2025 and 2024 | — | — | ||||||
| Series B Preferred Stock, $0.0001 par value; 437,927 shares authorized, issued and outstanding as of December 31, 2025 and 2024 | — | — | ||||||
| Preferred stock, $0.0001 par value; 9,427,168.437 shares authorized as of December 31, 2025 and 2024; no shares issued and outstanding as of December 31, 2025 and 2024 | — | — | ||||||
| Common stock, $0.0001 par value; 350,000,000 shares authorized as of December 31, 2025 and 2024; 26,011,106 and 25,767,369 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 3 | 3 | ||||||
| Additional paid-in capital | 700,706 | 689,887 | ||||||
| Accumulated deficit | (822,373 | ) | (692,071 | ) | ||||
| Accumulated other comprehensive loss | (4,576 | ) | (4,621 | ) | ||||
| Total stockholders’ deficit | (126,240 | ) | (6,802 | ) | ||||
| Total liabilities and stockholders’ deficit | $ | 296,411 | $ | 435,023 | ||||
| Cartesian Therapeutics, Inc. and Subsidiaries Consolidated Statements of Operations and Comprehensive Loss (Amounts in thousands, except share and per share data) | ||||||||
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Revenues: | ||||||||
| Collaboration and license | $ | 400 | $ | 38,275 | ||||
| Grant | 2,397 | 638 | ||||||
| Total revenues | 2,797 | 38,913 | ||||||
| Operating expenses: | ||||||||
| Research and development | 58,034 | 45,105 | ||||||
| General and administrative | 31,468 | 30,126 | ||||||
| Impairment of indefinite-lived intangible and long-lived assets | 56,700 | 7,579 | ||||||
| Total operating expenses | 146,202 | 82,810 | ||||||
| Operating loss | (143,405 | ) | (43,897 | ) | ||||
| Other income (expense): | ||||||||
| Interest income | 6,579 | 7,386 | ||||||
| Gain on change in fair value of warrant liabilities | 3,695 | 2,558 | ||||||
| Loss on change in fair value of contingent value right liability | (4,354 | ) | (36,900 | ) | ||||
| Loss on change in fair value of forward contract liabilities | — | (6,890 | ) | |||||
| Other (expense) income, net | (2,010 | ) | 606 | |||||
| Total other income (expense), net | 3,910 | (33,240 | ) | |||||
| Loss before income taxes | (139,495 | ) | (77,137 | ) | ||||
| Income tax benefit (expense) | 9,193 | (287 | ) | |||||
| Net loss | $ | (130,302 | ) | $ | (77,424 | ) | ||
| Other comprehensive income (loss): | ||||||||
| Foreign currency translation adjustment | 45 | (21 | ) | |||||
| Total comprehensive loss | $ | (130,257 | ) | $ | (77,445 | ) | ||
| Net loss | $ | (130,302 | ) | $ | (77,424 | ) | ||
| Net loss per share allocable to common stockholders: | ||||||||
| Basic | $ | (5.02 | ) | $ | (4.48 | ) | ||
| Diluted | $ | (5.02 | ) | $ | (4.49 | ) | ||
| Weighted-average common shares outstanding: | ||||||||
| Basic | 25,973,329 | 17,276,822 | ||||||
| Diluted | 25,973,329 | 17,357,943 | ||||||
Investor Contact
Megan LeDuc
Associate Director of Investor Relations
[email protected]
Media Contact
David Rosen
Argot Partners
[email protected]
| 2 hours | |
| Feb-23 | |
| Feb-03 | |
| Jan-14 | |
| Jan-09 | |
| Jan-06 | |
| Dec-18 | |
| Nov-13 | |
| Nov-06 | |
| Oct-30 | |
| Oct-30 | |
| Oct-28 | |
| Oct-21 | |
| Oct-03 | |
| Aug-28 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite